Capital at risk. Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. EIS tax relief depends on personal circumstances and is subject to HMRC rules. Take 2 minutes to learn more.
The Challenge
The Challenge Facing Cancer Diagnostics
Current Limitations in Cancer Monitoring
Traditional cancer monitoring methods present significant clinical and logistical challenges. Tissue biopsies are invasive, difficult to repeat and provide only a snapshot of tumour biology at a single point in time.
- Traditional biopsies are invasive and difficult to repeat
- Monitoring often relies on imaging scans with limited biological detail
- Treatment decisions are frequently reactive rather than proactive
- Personalisation of therapy remains limited by available data
- Delays between testing and results can affect clinical decision-making
The Frontier Diagnostics CTC Solution
Frontier Diagnostics is developing a blood-based platform designed to capture and analyse circulating tumour cells from a simple blood sample, providing researchers and clinicians with a less invasive, repeatable monitoring approach.
- Circulating tumour cell (CTC) analysis from a blood sample
- Blood-based monitoring - less invasive than tissue biopsy
- Designed to support earlier biological insight
- Enables personalised treatment support and ongoing surveillance
- Platform designed for central laboratory and on-site deployment
Tax Advantages
Enterprise Investment Scheme (EIS) Tax Benefits for Qualifying Investors
Frontier Diagnostics is structured as an EIS-qualifying investment. The following reliefs may be available to eligible UK investors, subject to individual circumstances and HMRC rules.
Leadership
Frontier Diagnostics Management Team
Frontier Diagnostics is led by an experienced team with backgrounds across diagnostics, oncology, life sciences and corporate finance.
Investor Questions
Frequently Asked Questions
Common questions from prospective investors about Frontier Diagnostics, the EIS investment opportunity and our cancer diagnostics technology.
What is Frontier Diagnostics?
Frontier Diagnostics Ltd (Company No. 14416890) is a UK-registered medical diagnostics company developing proprietary Circulating Tumour Cell (CTC) technology for blood-based cancer monitoring. The company is developing next-generation liquid biopsy solutions targeting the global oncology diagnostics market.
Is Frontier Diagnostics EIS qualifying?
Frontier Diagnostics is structured as an EIS-qualifying investment opportunity. Eligible UK investors may benefit from up to 30% income tax relief, Capital Gains Tax deferral, tax-free growth and Inheritance Tax relief under the Enterprise Investment Scheme, subject to individual circumstances and HMRC rules.
What is the minimum investment?
The minimum investment in Frontier Diagnostics is £12,000. The opportunity is open to High Net Worth Individuals, Sophisticated Investors and Professional Investors only.
What is Circulating Tumour Cell (CTC) technology?
CTC technology involves capturing and analysing cancer cells that have shed from a primary tumour into the bloodstream. Frontier Diagnostics is developing a blood-based platform that uses CTC analysis to support cancer monitoring through a simple blood sample - a less invasive alternative to traditional tissue biopsy.
What is liquid biopsy technology?
Liquid biopsy is a minimally invasive diagnostic approach that analyses biological markers - such as circulating tumour cells - from a blood sample rather than requiring surgical tissue removal. Frontier Diagnostics is developing a liquid biopsy platform for blood-based cancer monitoring and precision oncology applications.
How does EIS tax relief work?
The Enterprise Investment Scheme (EIS) is a UK government scheme designed to encourage investment in early-stage, high-growth companies. Eligible investors can claim up to 30% income tax relief, defer Capital Gains Tax, benefit from tax-free growth on qualifying shares, and claim loss relief if the investment fails. Tax reliefs depend on individual circumstances and are subject to change.
How do I invest in Frontier Diagnostics?
Eligible investors should request the Investor Factsheet by completing the form on this page. A member of the Frontier Diagnostics Investor Relations team will be in touch to discuss the opportunity in detail.
What are the risks of investing?
Investing in early-stage companies involves significant risk. Capital is at risk and investors may lose some or all of their investment. EIS investments are illiquid and there is no guarantee of a return. Prospective investors should seek independent financial and tax advice before making any investment decision.
Investor Factsheet
Download the Frontier Diagnostics Investor Factsheet
The investor factsheet provides a comprehensive overview of the Frontier Diagnostics investment opportunity, including company background, technology overview, market opportunity, investment terms and risk information.
Factsheet Contents
- Company Overview and Background
- Technology and Product Summary
- Market Opportunity and Competitive Landscape
- Investment Terms and EIS Summary
- Use of Funds
- Management Team Profiles
For High Net Worth, Sophisticated and Professional Investors only. Capital at risk.